<DOC>
	<DOCNO>NCT00217607</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well paclitaxel work treat patient locally advance metastatic soft tissue angiosarcoma lymphangiosarcoma remove surgery .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Locally Advanced Metastatic Soft Tissue Angiosarcoma Lymphangiosarcoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-month objective response rate patient locally advanced metastatic , unresectable soft tissue angiosarcoma lymphangiosarcoma treat paclitaxel . Secondary - Determine 4- 6-month response rate patient treat drug . - Determine tolerability drug patient . - Determine time disease progression overall survival patient treated drug . - Determine clinical criterion predict response patient treated drug . - Correlate efficacy drug expression gene involve angiogenesis regulation patient . OUTLINE : This multicenter study . Patients receive paclitaxel IV day 1 , 8 , 15 . Treatment repeat every 28 day 6 course . PROJECTED ACCRUAL : A total 15-30 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue angiosarcoma lymphangiosarcoma Locally advance metastatic disease Unresectable disease Angiosarcomas previously irradiate area allow provided disease clearly progressive Measurable disease No Kaposi 's sarcoma PATIENT CHARACTERISTICS : Age 18 70 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 3 time upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 time ULN No severe liver failure Renal Creatinine clearance &gt; 60 mL/min No severe kidney failure Cardiovascular LVEF ≥ 50 % Other Not pregnant nursing Fertile patient must use effective contraception No weight loss ≥ 20 % body weight prior illness Patient must amenable receive care day No HIV positivity No clinical neuropathy No known allergy study drug component ( e.g. , Cremophor EL ) No progressive malignant tumor No chronic illness ( somatic psychiatric ) would preclude study compliance followup No psychological , geographical , social reason would preclude study followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 2 prior course chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify Other No concurrent anticancer therapy No concurrent participation another therapeutic investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>